Aprea Therapeutics News

Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating

TipRanksApr 12 11:35 ET

Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis

TipRanksApr 11 06:26 ET

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

TipRanksMar 27 16:05 ET

Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)

TipRanksMar 27 08:20 ET

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024

TipRanksMar 26 11:15 ET

Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline

TipRanksMar 19 15:05 ET

Buy Rating Affirmed for Aprea Therapeutics Amid Strong Clinical Results and Strategic Advantages

TipRanksJan 11 12:35 ET

Aprea Therapeutics Bags a 'Buy' Rating: Promising Clinical Developments and Strong Financial Position Highlighted

TipRanksNov 11, 2023 07:05 ET

Positive Financial Health and Promising Clinical Trials Propel Aprea Therapeutics to a Buy Rating: An Analysis by H.C. Wainwright

TipRanksNov 10, 2023 06:57 ET

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

BenzingaNov 1, 2023 06:59 ET

Aprea Therapeutics Analyst Ratings

BenzingaNov 1, 2023 06:56 ET

Aprea Therapeutics' Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy's Buy Rating

TipRanksOct 18, 2023 13:05 ET

Positive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Rating

TipRanksOct 16, 2023 11:06 ET

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

BenzingaSep 13, 2023 06:30 ET

Aprea Therapeutics Analyst Ratings

BenzingaSep 13, 2023 06:29 ET

Maxim Group Sticks to Their Buy Rating for Aprea Therapeutics (APRE)

TipRanksAug 11, 2023 09:45 ET

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

BenzingaAug 10, 2023 12:03 ET

Analysts Are Bullish on These Healthcare Stocks: Citius Pharmaceuticals (CTXR), Aprea Therapeutics (APRE)

TipRanksAug 10, 2023 10:30 ET

Aprea Therapeutics (APRE) Receives a Buy From H.C. Wainwright

TipRanksMay 16, 2023 06:25 ET

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

BenzingaMay 16, 2023 06:23 ET